National Meeting Highlights from the American Pain Society 2012
Release Date: June 08, 2012
Expiration Date: June 08, 2013
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Presented in Collaboration with the American Pain Society
This educational initiative offers highlights from five key sessions held at the 31st Annual Scientific Meeting of the American Pain Society.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in pain management.
Upon completion of this educational activity, participants should be able to:
- Identify and evaluate therapeutic implications of new conference data from the American Pain Society 2012 meeting related to pain management
Introduction: Jeffrey A. Gudin, MD
Part 1: Charles E. Inturrisi, PhD
Part 2: Michael Schatman, PhD, CPE
Part 3: Charles E. Argoff, MD
Part 4: Jeffrey A. Gudin, MD
Part 5: Lynn R. Webster, MD, FACPM, FASAM
Instructions for Participation and Credit
This activity is eligible for credit through June 8, 2013. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Jeffrey A. Gudin, MD
Pain Management Center
Englewood Hospital and Medical Center
Englewood, New Jersey
Dr. Jeffrey A. Gudin received his medical degree from Albany Medical College in Albany, New York. Following a transitional internship in surgery, medicine, and anesthesiology at St. Barnabas Medical Center in Livingston, New Jersey, he completed a residency in anesthesiology at Yale University School of Medicine. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching. He is currently director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey, an affiliate of the Mount Sinai School of Medicine. Dr. Gudin is board certified in pain medicine and anesthesiology, and is board eligible in addiction medicine.
An active speaker in the field of pain management, Dr. Gudin has been interviewed on various television news channels, including CBS, and other national news networks. Dr. Gudin has also been quoted in The New York Times and various regional newspapers in New Jersey and Connecticut. His clinical and research focus includes pain management, regional anesthesia, and preemptive analgesia, as well as increasing clinician awareness of pain assessment and management.
Charles E. Inturrisi, PhD
Professor of Pharmacology
Weill Medical College of Cornell University
New York, New York
Dr. Charles Inturrisi received his doctorate degree in pharmacology from Tulane University, New Orleans, Louisiana. He is currently a professor of pharmacology at Weill Medical College of Cornell University in New York City. He also has appointments in the Neuroscience Program at Weill and with the Pain and Palliative Care Service, Memorial Sloan-Kettering Cancer Center and with the Drug Abuse Center at The Rockefeller University.
Dr. Inturrisi is the past president of the American Pain Society, as well as a member of the American Association for the Advancement of Science, the International Association for the Study of Pain, and the Society for Neuroscience, among others. In addition, he is on the editorial board of the Journal of Pain and Symptom Management, and is an ad hoc scientific review for numerous journals including Life Sciences, The Journal of Neuroscience, Journal of Neurochemistry, and Anesthesiology. Dr. Inturrisi’s basic and clinical research interests are in the role of glutamate receptors in pain and in opioid tolerance, dependence and addictive behaviors. His research is directed at the discovery of new treatments for pain and drug addiction.
Michael Schatman, PhD, CPE
Foundation for Ethics in Pain Care
Dr. Michael Schatman is a clinical psychologist who has spent the past 26 years working in multidisciplinary chronic pain management. He is currently the executive director of the Foundation for Ethics in Pain Care in Bellevue, Washington, and maintains a part-time practice in pain psychology in Bellevue as well.
Dr. Schatman is the author of over 40 journal articles and book chapters on various aspects of chronic pain management, and lectures regularly on pain management both locally and nationally. Additionally, he is the editor of Ethical Issues in Chronic Pain Management and Chronic Pain Management: Guidelines for Multidisciplinary Program Development and is on the editorial review boards of Pain Medicine and Psychological Injury and Law. Dr. Schatman is the secretary of the Western Pain Society, the chairperson of the Ethics Special Interest Group of the American Pain Society, is a member of the Ethics Committee of the American Pain Society, and is a member of the Executive Advisory Board of the Association for Scientific Advancement in Psychological Injury and Law. He served for two years on the Clinical Advisory Board of the American Society of Pain Educators, on whose Board of Directors he now sits.
Charles E. Argoff, MD
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, New York
Dr. Charles Argoff received his medical degree from Northwestern University’s Feinberg School of Medicine in Chicago, Illinois. He completed an internship in the Department of Medicine, a residency in the Department of Neurology at the State University of New York in Stony Brook, and a fellowship in developmental and metabolic neurology at the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS). He is currently a professor of neurology at Albany Medical College and director of the Comprehensive Pain Center at Albany Medical Center in New York.
Dr. Argoff is a member of the International Association for the Study of Pain, the American Academy of Pain Medicine, and the American Academy of Neurology, among others. He serves on the editorial board of the Clinical Journal of Pain, and as a reviewer for the Journal of Pain, Brain, JAMA, Archives of Physical Medicine and Rehabilitation, Journal of Musculoskeletal Pain, Journal of Pain and Symptom Management, and the Clinical Journal of Pain. He is co-editor of the neuropathic pain section of Pain Medicine and is one of the editors of the recently published textbook Raj’s Practical Management of Pain. In addition, Dr. Argoff has served as a guest editor for and published articles in the Clinical Journal of Pain, and Current Pain and Headache Reports, among others. He has written on many types of pain, including myofascial pain, neuropathic pain, spinal and radicular pain, and on such treatments as topical analgesics, interventional pain management, botulinum toxins, and oral analgesics. Dr. Argoff had an active role in the development of the diabetic peripheral neuropathic pain guidelines published in Mayo Clinic Proceedings, and he has contributed to other published neuropathic pain treatment guidelines.
Lynn R. Webster, MD, FACPM, FASAM
Salt Lake City, Utah
Dr. Lynn Webster earned his medical degree from the University of Nebraska and completed his residency in the University of Utah’s Department of Anesthesiology. He is medical director at CRILifetree in Salt Lake City, Utah and is also the co-founder of LifeSource, a non-profit foundation established in 2006 to provide education about pain-related issues as well as fund and conduct research. LifeSource’s first project, “Zero Unintentional Deaths,” was developed to educate physicians, chronic pain sufferers, and all communities about unintentional overdose deaths relating to methadone and other prescription medications.
Dr. Webster is board certified in anesthesiology and pain medicine with additional certification in addiction medicine; he is currently on the Board of Directors and serves as treasurer for the American Academy of Pain Medicine. He is past president of the Utah Academy of Pain Medicine and an active national spokesman for improving access to pain therapies.
Dr. Webster lectures extensively on the subject of preventing opioid abuse and criminal diversion in chronic pain patients. He has authored over 100 scientific abstracts, journal articles and recently published the book, Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-12-317-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 12-317-285
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jeffrey Gudin has received honoraria related to speakers’ bureau activities from Cephalon, Inc., King Pharmaceuticals, Inc., Pfizer Inc., and Purdue Pharma L.P.
Dr. Gudin has received no honoraria for the participation in this activity.
Dr. Charles Inturrisi and Dr. Michael Schatman have disclosed no relevant financial relationships.
Dr. Inturrisi and Dr. Schatman have received no honoraria for the participation in this activity.
Dr. Charles Argoff has received honoraria related to speaker’s bureau and formal advisory activities from Eli Lilly and Company, Endo Pharmaceuticals Inc., Forest Pharmaceuticals, King Pharmaceuticals, Inc., Pfizer Inc., and PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and as well as formal advisory activities from Bristol-Myers Squibb, Jazz Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, and Solvay Pharmaceuticals, Inc. He has received grant support related to research activities from Eli Lilly, Endo, Forest, and Pfizer.
Dr. Argoff has received no honoraria for the participation in this activity.
Dr. Lynn Webster has received honoraria related to formal advisory activities and as a consultant from American Academy of Pain Management, American Board of Pain Medicine, Boston Scientific Corporation, Covidien, Iroko Pharmaceuticals, LLC, Medtronic, Inc., Nektar, Pfizer Inc., and Salix Pharmaceuticals, Inc.
Dr. Webster has received no honoraria for the participation in this activity.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Bronwyn Boyes, PharmD, director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Drs. Gudin and Schatman have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Gudin, Schatman, and Webster have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Drs. Inturrisi, Argoff, and Webster have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Inturrisi and Argoff have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 8.0 or higher, or Firefox 4.0 or higher, a computer running Windows® XP, Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Purdue Pharma L.P, Endo Pharmaceuticals Inc., Teva Pharmaceuticals, Covidien, and Salix Pharmaceuticals, Inc.
©2012 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.